A National Translational Science Network of Precision-Based Immunotherapy for Primary Liver Cancer (PLC)
The primary objective of the NCI-CLARITY study is to establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of primary liver cancer (PLC) development and progression. Secondary objectives include predicting overall and progression-free survival following immunotherapy. In the retrospective phase, anonymous archival tissue from PLC patients was obtained from five participating sites. Whole exome and transcriptome sequencing was generated and used to predict overall survival in response to immunotherapy.
- Type: Longitudinal
- Archiver: The database of Genotypes and Phenotypes (dbGaP)